Global Oncology Academy - Global Oncology Academy

Global Oncology Academy

Global Oncology Academy

Enhance your practice with CME
and tools that focus on the management
and treatment of patients with cancer.

Popular

NEW EPISODE
De Novo mHSPC: Recognizing the Patients Who Need More
De Novo mHSPC: Recognizing the Patients Who Need More
MinuteCE®
De Novo mHSPC: Recognizing the Patients Who Need More
Scott T. Tagawa, MD, MS; Mary-Ellen Taplin, MD
1.00 program credit
- Scott T. Tagawa, MD, MS
- Mary-Ellen Taplin, MD
1.00 program credit
EHA 2026: Sonrotoclax Plus Zanubrutinib in Frontline CLL
EHA 2026: Sonrotoclax Plus Zanubrutinib in Frontline CLL
Oncology and Hematology
EHA 2026: Sonrotoclax Plus Zanubrutinib in Frontline CLL
Chan Y. Cheah, MBBS
- Chan Y. Cheah, MBBS
NEW EPISODE
Molecular Profiling in mHSPC: Informing Treatment Selection
Molecular Profiling in mHSPC: Informing Treatment Selection
MinuteCE®
Molecular Profiling in mHSPC: Informing Treatment Selection
Scott T. Tagawa, MD, MS; Mary-Ellen Taplin, MD
1.00 program credit
- Scott T. Tagawa, MD, MS
- Mary-Ellen Taplin, MD
1.00 program credit
The Evolving TROP2-directed ADC Landscape in Metastatic NSCLC
The Evolving TROP2-directed ADC Landscape in Metastatic NSCLC
Oncology and Hematology
The Evolving TROP2-directed ADC Landscape in Metastatic NSCLC
Nicolas Girard, MD; Louise Lim, MD
- Nicolas Girard, MD
- Louise Lim, MD
- Jacob Sands, MD
- Stephanie McDonald, MSN, FNP-BC, AOCNP
Addressing Oncology-Related Infertility Through Collaborative Care
Addressing Oncology-Related Infertility Through Collaborative Care
Clinician's Roundtable
Addressing Oncology-Related Infertility Through Collaborative Care
Irene Su, MD, MSCE
- Irene Su, MD, MSCE
6-Year CheckMate 9LA Data in PD-L1-Negative NSCLC: Implications for Care
6-Year CheckMate 9LA Data in PD-L1-Negative NSCLC: Implications for Care
Project Oncology®
6-Year CheckMate 9LA Data in PD-L1-Negative NSCLC: Implications for Care
Steve Jackson, PharmD; Lyudmila A. Bazhenova, MD
- Steve Jackson, PharmD
- Lyudmila A. Bazhenova, MD
NEW EPISODE
ELEVATE: Elacestrant Plus Capivasertib in Advanced Breast Cancer
ELEVATE: Elacestrant Plus Capivasertib in Advanced Breast Cancer
MinuteCE®
ELEVATE: Elacestrant Plus Capivasertib in Advanced Breast Cancer
Aditya Bardia, MD, MPH, FASCO
0.50 program credits
- Aditya Bardia, MD, MPH, FASCO
0.50 program credits
NEW EPISODE
SERENA-6: Acting on ESR1 Mutations in Advanced Breast Cancer
SERENA-6: Acting on ESR1 Mutations in Advanced Breast Cancer
MinuteCE®
SERENA-6: Acting on ESR1 Mutations in Advanced Breast Cancer
Erica L. Mayer, MD, MPH
0.50 program credits
- Erica L. Mayer, MD, MPH
0.50 program credits

Medical News

$talquetamab and daratumumab in relapsed or refractory myeloma$ $talquetamab and daratumumab in relapsed or refractory myeloma$
Medical News
Talquetamab and Daratumumab in Relapsed or Refractory Myeloma
06/18/2026
Read more
Medical News
Olaparib Plus Radium-223 Improves rPFS in COMRADE
06/18/2026
Read more
Medical News
Text Messaging and FIT Completion in a Quality Improvement Trial
06/18/2026
Read more
Medical News
PORTEC-4a Trial Reports Molecular Profile Guided Adjuvant Treatment
06/17/2026
Read more

CME/CE

NEW EPISODE
ADT Intensification: The Evidence You Can’t Afford to Miss
ADT Intensification: The Evidence You Can’t Afford to Miss
MinuteCE®
ADT Intensification: The Evidence You Can’t Afford to Miss
Scott T. Tagawa, MD, MS; Mary-Ellen Taplin, MD
1.00 program credit
- Scott T. Tagawa, MD, MS
- Mary-Ellen Taplin, MD
1.00 program credit
NEW EPISODE
Ongoing Trials in Oral Targeted Strategies in Breast Cancer
Ongoing Trials in Oral Targeted Strategies in Breast Cancer
MinuteCE®
Ongoing Trials in Oral Targeted Strategies in Breast Cancer
Aditya Bardia, MD, MPH, FASCO
0.50 program credits
- Aditya Bardia, MD, MPH, FASCO
0.50 program credits
MinuteCE®
Rapid Data Pulses From ASCO 2026: Emerging Data on Oral Targeted Strategies in Breast Cancer
Aditya Bardia, MD, MPH, FASCO; Erica L. Mayer, MD, MPH
0.50 credits 3 episodes
- Aditya Bardia, MD, MPH, FASCO
- Erica L. Mayer, MD, MPH
0.50 credits 3 episodes
Before the Scalpel: Identifying Candidates for Perioperative Immunotherapy
Before the Scalpel: Identifying Candidates for Perioperative Immunotherapy
MinuteCE®
Before the Scalpel: Identifying Candidates for Perioperative Immunotherapy
Adam J. Luginbuhl, MD
0.50 program credits
- Adam J. Luginbuhl, MD
0.50 program credits

Clinical Practice

NEW EPISODE
Targeting PTEN: Why It Matters
Targeting PTEN: Why It Matters
MinuteCE®
Targeting PTEN: Why It Matters
Scott T. Tagawa, MD, MS; Mary-Ellen Taplin, MD
1.00 program credit
- Scott T. Tagawa, MD, MS
- Mary-Ellen Taplin, MD
1.00 program credit
EHA 2026: Long-Term Zanubrutinib Outcomes
EHA 2026: Long-Term Zanubrutinib Outcomes
Oncology and Hematology
EHA 2026: Long-Term Zanubrutinib Outcomes
Alessandra Tedeschi, MD
- Alessandra Tedeschi, MD
DESTINY-Breast05 Findings Lead to New Indication for Trastuzumab Deruxtecan as Adjuvant Treatment for Residual Invasive Disease
DESTINY-Breast05 Findings Lead to New Indication for Trastuzumab Deruxtecan as Adjuvant Treatment for Residual Invasive Disease
Oncology and Hematology
DESTINY-Breast05 Findings Lead to New Indication for Trastuzumab Deruxtecan as Adjuvant Treatment for Residual Invasive Disease
Sara A. Hurvitz, MD, FACP
- Sara A. Hurvitz, MD, FACP
TROPION-Breast02: Evidence for the Approval of Datopotamab Deruxtecan for Patients With mTNBC Ineligible for Immunotherapy
TROPION-Breast02: Evidence for the Approval of Datopotamab Deruxtecan for Patients With mTNBC Ineligible for Immunotherapy
Oncology and Hematology
TROPION-Breast02: Evidence for the Approval of Datopotamab Deruxtecan for Patients With mTNBC Ineligible for Immunotherapy
Tiffany Traina, MD, FASCO
- Tiffany Traina, MD, FASCO

Programs

NEW EPISODE
Winning the Battle Against Side Effects: Adverse Event Management in HSPC
Winning the Battle Against Side Effects: Adverse Event Management in HSPC
MinuteCE®
Winning the Battle Against Side Effects: Adverse Event Management in HSPC
Scott T. Tagawa, MD, MS; Mary-Ellen Taplin, MD
1.00 program credit
- Scott T. Tagawa, MD, MS
- Mary-Ellen Taplin, MD
1.00 program credit
Assessing and Interpreting pCR in Perioperative NSCLC
Assessing and Interpreting pCR in Perioperative NSCLC
Project Oncology®
Assessing and Interpreting pCR in Perioperative NSCLC
Steve Jackson, PharmD; Alexander Spira, MD, PhD, FACP
- Steve Jackson, PharmD
- Alexander Spira, MD, PhD, FACP
Decoding epNECs: Diagnostic Challenges and Emerging Strategies
Decoding epNECs: Diagnostic Challenges and Emerging Strategies
Project Oncology®
Decoding epNECs: Diagnostic Challenges and Emerging Strategies
Brian P. McDonough, MD, FAAFP; Andrew E. Hendifar, MD
- Brian P. McDonough, MD, FAAFP
- Andrew E. Hendifar, MD
Navigating Classification of High-Grade Neuroendocrine Neoplasms
Navigating Classification of High-Grade Neuroendocrine Neoplasms
Project Oncology®
Navigating Classification of High-Grade Neuroendocrine Neoplasms
Charles Turck, PharmD, BCPS, BCCCP; Rohit Thummalapalli, MD
- Charles Turck, PharmD, BCPS, BCCCP
- Rohit Thummalapalli, MD